Literature DB >> 27262695

Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.

Kristian Gaarn du Jardin1, Heidi Kaastrup Müller2, Betina Elfving2, Elena Dale3, Gregers Wegener4, Connie Sanchez5.   

Abstract

A single i.v. infusion of ketamine, classified as an N-methyl-d-aspartate (NMDA) receptor antagonist, may alleviate depressive symptoms within hours of administration in treatment resistant depressed patients, and the antidepressant effect may last for several weeks. These unique therapeutic properties have prompted researchers to explore the mechanisms mediating the antidepressant effects of ketamine, but despite many efforts, no consensus on its antidepressant mechanism of action has been reached. Recent preclinical reports have associated the neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) with the antidepressant-like action of ketamine. Here, we review the current evidence for a serotonergic role in ketamine's antidepressant effects. The pharmacological profile of ketamine may include equipotent activity on several non-NMDA targets, and the current hypotheses for the mechanisms responsible for ketamine's antidepressant activity do not appear to preclude the possibility that non-glutamate neurotransmitters are involved in the antidepressant effects. At multiple levels, the serotonergic and glutamatergic systems interact, and such crosstalk could support the notion that changes in serotonergic neurotransmission may impact ketamine's antidepressant potential. In line with these prospects, ketamine may increase 5-HT levels in the prefrontal cortex of rats, plausibly via hippocampal NMDA receptor inhibition and activation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. In addition, a number of preclinical studies suggest that the antidepressant-like effects of ketamine may depend on endogenous activation of 5-HT receptors. Recent imaging and behavioral data predominantly support a role for 5-HT1A or 5-HT1B receptors, but the full range of 5-HT receptors has currently not been systematically investigated in this context. Furthermore, the nature of any 5-HT dependent mechanism in ketamine's antidepressant effect is currently not understood, and therefore, more studies are warranted to confirm this hypothesis and explore the specific pathways that might implicate 5-HT.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressant; Glutamate; Ketamine; Pharmacology; Serotonin

Mesh:

Substances:

Year:  2016        PMID: 27262695     DOI: 10.1016/j.pnpbp.2016.05.007

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

1.  Abrogated Freud-1/Cc2d1a Repression of 5-HT1A Autoreceptors Induces Fluoxetine-Resistant Anxiety/Depression-Like Behavior.

Authors:  Faranak Vahid-Ansari; Mireille Daigle; M Chiara Manzini; Kenji F Tanaka; René Hen; Sean D Geddes; Jean-Claude Béïque; Jonathan James; Zul Merali; Paul R Albert
Journal:  J Neurosci       Date:  2017-11-03       Impact factor: 6.167

2.  Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography.

Authors:  Marie Spies; Gregory M James; Neydher Berroterán-Infante; Harald Ibeschitz; Georg S Kranz; Jakob Unterholzner; Mathis Godbersen; Gregor Gryglewski; Marius Hienert; Johannes Jungwirth; Verena Pichler; Birgit Reiter; Leo Silberbauer; Dietmar Winkler; Markus Mitterhauser; Thomas Stimpfl; Marcus Hacker; Siegfried Kasper; Rupert Lanzenberger
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

3.  The monoaminergic pathways and inhibition of monoamine transporters interfere with the antidepressive-like behavior of ketamine.

Authors:  Glauce Socorro de Barros Viana; Cecilia Coelho Xavier; Eduardo Mulato do Vale; Maria Janice Pereira Lopes; Viviane de Jesus Alves; Roberta de Oliveira Costa; Kelly Rose Tavares Neves
Journal:  IBRO Rep       Date:  2017-12-02

4.  The influence of subanaesthetic ketamine on regional cerebral blood flow in healthy dogs measured with 99mTc-HMPAO SPECT.

Authors:  Lise Vlerick; Kathelijne Peremans; Robrecht Dockx; Kurt Audenaert; Chris Baeken; Bart De Spiegeleer; Jimmy Saunders; Ingeborgh Polis
Journal:  PLoS One       Date:  2018-12-18       Impact factor: 3.240

Review 5.  Ketamine and depression: a narrative review.

Authors:  Alexandrine Corriger; Gisèle Pickering
Journal:  Drug Des Devel Ther       Date:  2019-08-27       Impact factor: 4.162

6.  A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression.

Authors:  Mikael Tiger; Emma R Veldman; Carl-Johan Ekman; Christer Halldin; Per Svenningsson; Johan Lundberg
Journal:  Transl Psychiatry       Date:  2020-06-01       Impact factor: 6.222

7.  (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism.

Authors:  Yukio Ago; Wataru Tanabe; Momoko Higuchi; Shinji Tsukada; Tatsunori Tanaka; Takumi Yamaguchi; Hisato Igarashi; Rei Yokoyama; Kaoru Seiriki; Atsushi Kasai; Takanobu Nakazawa; Shinsaku Nakagawa; Kenji Hashimoto; Hitoshi Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2019-10-01       Impact factor: 5.176

Review 8.  Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review.

Authors:  Johanna Louise Keeler; Janet Treasure; Mario F Juruena; Carol Kan; Hubertus Himmerich
Journal:  Nutrients       Date:  2021-11-20       Impact factor: 5.717

9.  5-Hydroxytryptamine-Independent Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model.

Authors:  Kai Zhang; Chao Dong; Yuko Fujita; Atsuhiro Fujita; Kenji Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

Review 10.  Leptin in depression: a potential therapeutic target.

Authors:  Tongtong Ge; Jie Fan; Wei Yang; Ranji Cui; Bingjin Li
Journal:  Cell Death Dis       Date:  2018-10-26       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.